Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39319 GENERATION BIO CO. (Exact name of registrant as specified in its charter) Delaware 81-4301284 (State or other ...

For more information, please visit www.generationbio.com. Exhibit 99.1 Generation Bio Announces Third Quarter 2025 Financial Results CAMBRIDGE, MASS., November 5, 2025 -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company, today reported third quarter financial results. Third Quarter 2025 Financial Results About Generation Bio Generation Bio is a biotechnology company that was historically working to change what's possible for people living with T cell-driven autoimmune diseases. In August 2025, the ...

CAMBRIDGE, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company, today reported third quarter financial results. Third Quarter 2025 Financial Results Cash Position: Cash, cash equivalents, and marketable securities were $89.6 million as of September 30, 2025, compared to $185.2 million as of December 31, 2024. The company expects that its cash, cash equivalents, and marketable securities will fund its operating expenditures for the foreseeable future.R&D Expens ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

• Geoff McDonough, MD to step down as CEO & President and become Chair of the Company’s Board of Directors • Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President CAMBRIDGE, MASS., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, today announced that Geoff McDonough, MD will step down as Chief Executive Officer and President, and will Chair the company ...

Generation Bio Co. (GBIO) came out with a quarterly loss of $3.12 per share versus the Zacks Consensus Estimate of a loss of $2.8. This compares to a loss of $3.1 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.43%. A quarter ago, it was expected that this company would post a loss of $2.5 per share when it actually produced a loss of $2.2, delivering a surprise of +12%.Over the last four quarters, the company has surpasse ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR For the transition period from to Commission File Number: 001-39319 GENERATION BIO CO. (Exact name of registrant as specified in its charter) Delaware 81-4301284 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 301 Binne ...

Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results CAMBRIDGE, MASS., August 12, 2025 -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, today announced new data demonstrating that its cell-targeted lipid nanoparticle (ctLNP) system selectively delivered siRNA to T cells in non-human primates, reinforcing the comp ...

核心观点 - 公司公布其细胞靶向脂质纳米颗粒(ctLNP)系统在非人灵长类动物中实现首次siRNA递送至T细胞的数据 证实该平台具有高度选择性和有效性 [1][3] - 公司现金余额为1.414亿美元 同时通过3100万美元和解金解除了5800万美元租赁负债 [1][11] - 公司启动战略评估 考虑包括收购 合并或资产出售在内的战略方案 并实施裁员90%的重组计划 [5][6][7] 技术突破 - ctLNP采用专有"隐形"基底组成 避免脱靶摄取 通过表面生物配体实现高效选择性递送 [2] - 0.5 mg/kg剂量的ctLNP-siRNA在非人灵长类动物中实现β-2微球蛋白显著敲低 效果持续三周 且未诱导T细胞活化标志物 [3] - 先导siRNA候选物展示对LAT1和VAV1的强效敲低 这两个靶点与T细胞驱动的自身免疫疾病相关 [4][6] 财务数据 - 2025年第二季度现金及等价物1.414亿美元 较2024年底1.852亿美元减少23.7% [11][14] - 研发费用1550万美元 同比下降5.5% 行政费用770万美元 同比下降19.0% [11][16] - 净亏损2090万美元 每股亏损3.12美元 较去年同期亏损2040万美元略有扩大 [11][16] - 租赁和解支付3100万美元 解除5800万美元负债 预计第三季度完成 [11] 战略动向 - 保留TD Cowen作为顾问 评估战略方案 包括收购 合并或资产出售 [5] - 分阶段重组 8月中旬开始 10月底结束 预计裁员90% 涉及研发团队 [6][7] - 维持核心研发能力 同时寻求最大化股东价值的战略方案 [6]

反向股票分割 - 公司宣布将于2025年7月21日东部时间下午5点实施1比10的反向股票分割 旨在提高每股市场价格以满足纳斯达克全球精选市场的最低买入价要求 [1] - 反向分割后 流通股数量将从约6730万股缩减至约670万股 但授权股份数量和面值不变 股权激励计划中的股份数量和行权价格将按比例调整 [3] - 分割调整后的股票将于2025年7月22日开市时以现有交易代码"GBIO"和新CUSIP号码37148K 209开始交易 [2] 股东权益处理 - 不发行零碎股份 持有不足10股的股东将获得现金补偿而非零碎股 [4] - Computershare信托公司担任本次反向分割的交换代理和转让代理 电子持股股东无需任何操作 通过银行/经纪商持股的股东将由中介机构自动调整头寸 [5] 公司业务背景 - 公司专注于开发治疗T细胞驱动自身免疫疾病的疗法 通过细胞靶向脂质纳米颗粒(ctLNP)递送siRNA 在体内重编程T细胞以减少自身反应性T细胞的产生 [7] - 该技术平台结合选择性递送和细胞内基因精准调控机制 靶向传统难以成药的自身免疫疾病驱动基因 [7]